20 March 2024 - NICE has published final evidence-based recommendations on momelotinib dihydrochloride monohydrate (Omjjara) for the treatment of aduklts with myelofibrosis-related splenomegaly or symptoms.

Momelotinib dihydrochloride monohydrate is recommended as an option for the treatment of adults with myelofibrosis-related splenomegaly or symptoms with moderate to severe anaemia who have not been treated with a JAK inhibitor or have been treated with ruxolitinib phosphate, only if they have intermediate‑2 or high-risk myelofibrosis, and GSK provides momelotinib dihydrochloride monohydrate according to the commercial arrangement.

Read NICE technology appraisal guidance